NCT07448155

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

A Phase 1, Single Dose, Open-Label, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is being conducted to evaluate the pharmacokinetics, safety, and tolerability of INCA033989 following subcutaneous (SC) or intravenous administration (IV) n healthy adult participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	INCA033989	INCA033989 will be administered at protocol defined dose.

Timeline

• Start date: 2026-03-19
• Primary completion: 2026-05-23
• Completion: 2026-05-23
• First posted: 2026-03-04
• Last updated: 2026-04-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study